Drugs · Nov 19, 2026
The Pharmacological Basis of SGLT2 Inhibitor-Mediated Kidney Protection: From Proximal Tubular Mechanisms to Clinical Outcomes
By Zaitoon H, Abdul-Ghani M, DeFronzo RA
Diabetic kidney disease (DKD) remains the leading cause of chronic kidney disease (CKD) worldwide despite advances in glycemic control, blood pressure management, and renin–angiotensin–aldosterone system blockade. The introduction of sodium–glucose cotransporter 2 (SGLT2) inhibitors has fundamentally changed the management of CKD by consistently reducing kidney disease progression and cardiovascular events in patients both with and without diabetes. These findings indicate that the benefits of SGLT2 inhibition extend beyond glucose lowering and reflect broader effects on cardiorenal physiology. This review examines the pharmacological mechanisms underlying SGLT2 inhibitor-mediated kidney protection, integrating experimental evidence with findings from major clinical outcome trials. Current evidence supports a hierarchical mechanistic model in which inhibition of proximal tubular sodium–glucose reabsorption represents the primary pharmacological event, restoring tubule-glomerular feedback, reducing intraglomerular pressure, and lowering tubular transport workload. These upstream hemodynamic and metabolic effects are thought to initiate downstream improvements in kidney oxygen balance, mitochondrial function, inflammation, oxidative stress, and fibrosis, although the relative contribution of these pathways remains incompletely defined. We further examine how contemporary clinical trials validate this mechanistic framework across diverse CKD populations, including patients with and without diabetes and across a broad range of kidney function and albuminuria. Finally, we discuss the implications of these findings for phenotype-specific treatment strategies, rational combination therapy with complementary kidney-protective agents, and future directions in biomarker-guided precision medicine. Collectively, current evidence supports SGLT2 inhibitors as integrated cardiorenal therapies that modify fundamental determinants of CKD progression and provide the pharmacological foundation of contemporary kidney-protective treatment.
doi.org/10.1007/s40265-026-02416-9Open accessPubMed 43058342Interventions